Magdolna Simó

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Tomáš Kalinčík, J William L Brown, Neil P. Robertson et al. · The Lancet Neurology · 2017 · 162 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +16

Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis

Tomáš Kalinčík, Dana Horáková, Tim Spelman et al. · Annals of Neurology · 2014 · 159 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

Tomáš Kalinčík, Ibrahima Diouf, Sifat Sharmin et al. · Neurology · 2020 · 98 citations · Full text

Education, Neurology, Disability Management +16

Ultrasonography of MADSAM neuropathy: Focal nerve enlargements at sites of existing and resolved conduction blocks

Erika Scheidl, Josef Böhm, Magdolna Simó et al. · Neuromuscular Disorders · 2012 · 78 citations

Medicine, Neurology, Neuroscience +12